Yield10 Bioscience (OTCPK:YTEN) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

YTEN Stoklara Genel Bakış

YTEN temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Risk Analizi

Negatif hissedar öz sermayesi

Anlamlı bir piyasa değeri yok ( $699K )

Geliri 1 milyon ABD dolarından az ( $750K )

Kazançlar son 5 yılda yılda 5.5% oranında azaldı

+ 2 daha fazla risk

Yield10 Bioscience, Inc. Rakipler

Bellicum Pharmaceuticals

OTCPK:BLCM

US$879.5k

SQZ Biotechnologies

OTCPK:SQZB

US$678.3k

Gelesis Holdings

OTCPK:GLSH

US$850.7k

Vyant Bio

OTCPK:VYNT

US$1.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Yield10 Bioscience
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.76
52 Haftanın En Yüksek Seviyesi	US$17.26
52 Haftanın En Düşük Seviyesi	US$0.80
Beta	1.36
11 Aylık Değişim	-30.91%
3 Aylık Değişim	-5.00%
1 Yıllık Değişim	-89.95%
33 Yıllık Değişim	-99.45%
5 Yıllık Değişim	-99.88%
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Recent updates

Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06M

Aug 10

Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?

Nov 12

Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans

Jul 19

Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 18

Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Situation

Apr 14

Hissedar Getirileri

	YTEN	US Biotechs	US Pazar
7D	-22.4%	-1.6%	-0.7%
1Y	-89.9%	17.6%	32.5%

Getiri vs. Endüstri: YTEN geçen yıl % 22.1 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: YTEN geçen yıl % 34.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is YTEN's price volatile compared to industry and market?
YTEN volatility
YTEN Average Weekly Movement	33.3%
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

İstikrarlı Hisse Senedi Fiyatı: YTEN hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: YTEN 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 28% dan 33% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1992	29	Olly Peoples	www.yield10bio.com

Yield10 Bioscience, Inc. Amerika Birleşik Devletleri'nde Camelina yağlı tohumlarını kullanarak ürünleri ticarileştirmeye odaklanan bir tarımsal biyobilim şirketi olarak faaliyet göstermektedir. Ürünleri arasında yüksek düzeyde omega-3 yağ asitleri eikosapentanoik asit (EPA) ve dokosaheksanoik asit (DHA) üretimi için Camelina yağı; ve biyodizel, yenilenebilir dizel (RD) ve sürdürülebilir havacılık yakıtı (SAF) dahil olmak üzere biyoyakıtlar için düşük karbon yoğunluklu hammadde yağı olarak kullanım yer almaktadır. Şirket daha önce Metabolix, Inc. olarak biliniyordu ve Ocak 2017'de adını Yield10 Bioscience, Inc. olarak değiştirdi.

Yield10 Bioscience, Inc. Temel Bilgiler Özeti

Yield10 Bioscience'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
YTEN temel i̇stati̇sti̇kler
Piyasa değeri	US$712.39k
Kazançlar(TTM)	-US$12.70m
Gelir(TTM)	US$750.00k

0.7x

P/S Oranı

0.0x

F/K Oranı

YTEN aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
YTEN gelir tablosu (TTM)
Gelir	US$750.00k
Gelir Maliyeti	US$7.21m
Brüt Kâr	-US$6.46m
Diğer Giderler	US$6.25m
Kazançlar	-US$12.70m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-19.08
Brüt Marj	-860.93%
Net Kâr Marjı	-1,693.60%
Borç/Özkaynak Oranı	-16.0%

YTEN uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

YTEN Stoklara Genel Bakış

Ödüller

Risk Analizi

Yield10 Bioscience, Inc. Rakipler

OTCPK:BLCM

US$879.5k

OTCPK:SQZB

US$678.3k

OTCPK:GLSH

US$850.7k

OTCPK:VYNT

US$1.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Nuseed Nutritional US Inc. entered into an asset purchase agreement to acquire Substantially all assets of Yield10 Bioscience, Inc./Yield10 Oilseeds, Inc. from Yield10 Bioscience, Inc. (OTCPK:YTEN) and Yield10 Oilseeds, Inc. for $5 million.

Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from NASDAQ Composite Index

Yield10 Bioscience Announces Delisting from Nasdaq

Yield10 Bioscience Announces 1-for-24 Reverse Stock Split to Increase the Market Price Per Share of the its Common Stock to Maintain the Listing of its Common Stock on The Nasdaq Capital Market

Yield10 Bioscience, Inc., Annual General Meeting, Jun 07, 2024

Yield10 Bioscience Receives Written Notice from The Nasdaq Stock Market LLC Regarding Not Eligible for Second 180 Day Compliance Period for the Minimum Bid Price Rule Deficiency

Recent updates

Nuseed Nutritional US Inc. entered into an asset purchase agreement to acquire Substantially all assets of Yield10 Bioscience, Inc./Yield10 Oilseeds, Inc. from Yield10 Bioscience, Inc. (OTCPK:YTEN) and Yield10 Oilseeds, Inc. for $5 million.

Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from NASDAQ Composite Index

Yield10 Bioscience Announces Delisting from Nasdaq

Yield10 Bioscience Announces 1-for-24 Reverse Stock Split to Increase the Market Price Per Share of the its Common Stock to Maintain the Listing of its Common Stock on The Nasdaq Capital Market

Yield10 Bioscience, Inc., Annual General Meeting, Jun 07, 2024

Yield10 Bioscience Receives Written Notice from The Nasdaq Stock Market LLC Regarding Not Eligible for Second 180 Day Compliance Period for the Minimum Bid Price Rule Deficiency

Yield10 Bioscience, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Yield10 Bioscience, Inc. Announces the Plant Biosafety Office of the Canadian Food Inspection Agency Clear Genome-edited E3902 Camelina for Planting in Canada

Nasdaq Hearings Panel Grants Yield10 Bioscience, Inc. an Additional Extension to Remain Listed on the Nasdaq Capital Market Until May 13, 2024

Yield10 Bioscience, Inc. Provides an Update on Its Omega-3 Camelina Program

Yield10 Bioscience, Inc. Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil

Yield10 Bioscience Receives Non-Compliance Notice From Nasdaq

Yield10 Bioscience, Inc. Contemplates Bankruptcy.

Yield10 Bioscience, Inc. Contemplates Bankruptcy.

Yield10 Bioscience, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Yield10 Bioscience, Inc. Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant Camelina

Yield10 Bioscience, Inc. Receives Non-Compliance Notice from Nasdaq

Yield10 Bioscience, Inc. has completed a Composite Units Offering in the amount of $3.7375 million.

Price target decreased by 33% to US$9.83

Second quarter 2023 earnings released: US$0.64 loss per share (vs US$0.70 loss in 2Q 2022)

New major risk - Shareholder dilution

Yield10 Bioscience, Inc. to Report Q2, 2023 Results on Aug 14, 2023

New major risk - Market cap size

Yield10 Bioscience, Inc. Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in Camelina

New minor risk - Share price stability

Yield10 Bioscience Files Request for Regulatory Status Review Under Usda-Aphis’S Secure Rule Covering Elite Camelina Designed to Produce the EPA Component of Omega-3 Oil

Yield10 Bioscience Receives A Deficiency Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement for Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insider recently bought US$1m worth of stock

Yield10 Bioscience, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$14.67

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$14.67

Yield10 Bioscience, Inc. Begins Winter 2022/2023 Field Test and Seed Production Program

Yield10 Bioscience, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06M

Yield10 Bioscience, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Yield10 Bioscience, Inc. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$15.33

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Price target decreased to US$17.00

Yield10 Bioscience Announces Recent Advances in the Development of Camelina as A Production Platform for PHA Bioplastic

Yield10 Bioscience, Inc. Announces an Update on the Camelina Line E3902 Development Program

Yield10 Bioscience, Inc. to Report Q4, 2021 Results on Mar 09, 2022

Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?

Third quarter 2021 earnings released: US$0.49 loss per share (vs US$0.87 loss in 3Q 2020)

Consensus revenue estimates fall to US$890.0k

Price target decreased to US$21.50

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$0.92 loss in 2Q 2020)

Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans

Yield10 Bioscience, Inc. Begins 2021 Field Test and Seed Scale Up Program